Rockwell Medical Technologies (RMTI) Reports Q4 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Rockwell Medical, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results
March 14, 2019 6:50 AM EDTWIXOM, Mich., March 14, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company"), a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD), today reported financial results for the three months and full year ended December 31, 2018.
Recent Business Updates:
Launch of Dialysate Triferic The Company has developed a long-term, strategic plan for the Triferic portfolio. As part of this plan, the Company expects to launch Dialysate Triferic in the U.S. during the second quarter of... More